AIMS: Ginisortamab, a first-in-class human monoclonal antibody for the treatment of advanced solid tumours, binds to gremlin-1 and restores bone morphogenetic protein signalling. We used pharmacokinetic/pharmacodynamic (PK/PD) modelling to characterize the relationship between ginisortamab dose and serum gremlin-1 binding, using model-based simulations to inform ginisortamab-dose selection for ongoing clinical development. METHODS: Ginisortamab and total gremlin-1 serum concentration data were obtained from the monotherapy dose-escalation module of the ONC001 phase 1/2 multipart study in participants with solid tumours (NCT04393298). Population PK/PD models were generated using an iterative model-building process with nonlinear mixed effects. RESULTS: , 2.2 95% CI: 1.6-3.0) volume of distribution of ginisortamab, but no other tested covariates impacted ginisortamab-gremlin-1 binding kinetics. Estimated gremlin-1 turnover time was rapid (~23 95% CI: ~18-32 min). The developed PK/PD model was used to simulate ginisortamab dosing regimens; 1000 mg once-weekly and 2000 mg every 2 weeks were predicted to maintain target suppression ≥90% over the dosing interval at steady state. CONCLUSION: This population PK/PD model adequately described ginisortamab PK and binding to serum gremlin-1 in patients with advanced solid tumours. Dose simulations informed the level of gremlin-1 suppression and supported further clinical evaluation of several dosing regimens.
Wong et al. (Thu,) studied this question.